Impact News +++ SpaceX treibt die Aktien von AST SpaceMobile an. Erfolgreiche Satellitenmission stützt (Finanzen.net) +++ AST SPACEMOBILE Aktie -3,77%

AMARIN Aktie

>AMARIN Aktienkurs

13.75 EUR (TradegateBSX)

Ask: 14 EUR / 200 Stück

Bid: 13.5 EUR / 200 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

AMARIN Aktie über LYNX handeln

Intraday

1 Jahr

>AMARIN Performance

1 Woche: +7,4%

1 Monat: +10,4%

3 Monate: +2,2%

6 Monate: +18,0%

1 Jahr: +17,5%

laufendes Jahr: +16,5%

>AMARIN Aktie

Name:

AMARIN CORP.ADR NEW 2025

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US0231114044 / A41557

Symbol/ Ticker:

EH3 (Frankfurt) / AMRN (NASDAQ)

Kürzel:

FRA:EH3, ETR:EH3, EH3:GR, NASDAQ:AMRN

Index:

Webseite:

https://www.amarincorp.co..

Profil:

Amarin Corporation plc - American Depositary Receipt represents shares in Amarin Corporation plc, a pharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health in the United States, Europe, and in..
>Volltext..

Marktkapitalisierung:

277.32 Mio. EUR

Unternehmenswert:

16.88 Mio. EUR

Umsatz:

187.04 Mio. EUR

EBITDA:

-1.85 Mio. EUR

Nettogewinn:

-29.04 Mio. EUR

Gewinn je Aktie:

-1.4 EUR

Schulden:

4.81 Mio. EUR

Liquide Mittel:

113.04 Mio. EUR

Operativer Cashflow:

22.07 Mio. EUR

Bargeldquote:

1.71

Umsatzwachstum:

1.4%

Gewinnwachstum:

61.59%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

AMARIN

Letzte Datenerhebung:

17.06.26

>AMARIN Kennzahlen

Aktien/ Unternehmen:

Aktien: 20.98 Mio. St.

Frei handelbar: 99.59%

Leerverk. Aktien: 2.98%

Rückkaufquote: -0.04%

Mitarbeiter: 80

Umsatz/Mitarb.: 2.31 Mio. EUR

Analysten:

Analystenrating: Sell

Kursziel: -17.6%

Bewertung:

KGV: -

KGV lG: -

KUV: 1.48

KBV: 0.71

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 51.1%

Gewinnmarge: -15.52%

Operative Marge: -2.34%

Managementeffizenz:

Gesamtkaprendite: -5.18%

Eigenkaprendite: -7.31%

>AMARIN Peer Group

Gesundheit, Herz-Kreislauf- Behandlung/ Kardiologie

>AMARIN Chart & Kurs - NASDAQ

>AMARIN News

05.06.26 - 08:01	U.S. Supreme Court Ends Amarin Patent Fight, Hikma Prevails (AFX)
	LONDON (dpa-AFX) - The United States Supreme Court has ruled in favor of Hikma Pharmaceuticals PLC (HIK.L HKMPY) and its wholly owned subsidiary Hikma Pharmaceuticals USA Inc., effectively ending ......

04.06.26 - 23:42	Hikma comments on Supreme Court of the United States′ unanimous decision in favour of Hikma (PR Newswire)
	LONDON, June 4, 2026 /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc., (Hikma) offered the following comments on today's unanimous decision by the Supreme Court of the United States effectively ending Amarin's patent......

04.06.26 - 19:48	Amarin dealt blow as Supreme Court upholds ′skinny labels′ for generics (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.05.26 - 14:03	New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia (GlobeNewswire EN)
	DUBLIN and BRIDGEWATER, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new data from a post hoc analysis of the REDUCE-IT® trial presented at the European Atherosclerosis Society (EAS) Congress 2026 in Athens, Greece....

05.05.26 - 19:45	All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy (Zacks)
	Amarin (AMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

30.04.26 - 20:47	Amarin′s Q1 Loss Narrower Than Expected, Sales Increase Y/Y (Zacks)
	AMRN beats earnings and sales estimates as Vascepa sales rise and cost cuts take hold, while the partnered Europe strategy reshapes growth....

30.04.26 - 17:12	Amarin (AMRN) Q1 2026 Earnings Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

29.04.26 - 14:54	Amarin steigert Umsatz in Q1 2026 und profitiert von Restrukturierung (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

29.04.26 - 13:09	Amarin GAAP EPS of -$0.03 misses by $0.04, revenue of $45.1M beats by $1.33M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.04.26 - 13:03	Amarin Reports 2026 First Quarter Financial Results (GlobeNewswire EN)
	Total Revenue Increased Led by Higher International Sales...

21.04.26 - 19:12	Amarin (AMRN) Q2 2025 Earnings Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

21.04.26 - 18:24	Amarin (AMRN) Q3 2025 Earnings Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

15.04.26 - 14:03

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 (GlobeNewswire EN)

DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first quarter 2026 financial results and conduct a conference call on Wednesday, April 29, 2026. The Company will issue a press release detailing its first quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET....

08.04.26 - 14:03

American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction (GlobeNewswire EN)

DUBLIN and BRIDGEWATER, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin”), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today highlighted the important scientific and educational activities featured at the American College of Cardiology (ACC) Scientific Sessions 2026 that emphasized elevated and high triglycerides (TG) as a contributor to residual cardiovascular (CV) risk and the role that icosapent ethyl (IPE) plays in contemporary lipid and cardiovascular risk management....

18.03.26 - 13:33

Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline (GlobeNewswire EN)

DUBLIN and BRIDGEWATER, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin”), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the recommendation that the treatment of CV risk in patients with hypertriglyceridemia be part of a broader dyslipidemia management as discussed in the 2026 American College of Cardiology (ACC) / American Heart Association (AHA)/Multisociety Dyslipidemia Guideline Update.i ...

16.03.26 - 13:18

New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology′s (ACC) Annu (GlobeNewswire EN)

DUBLIN and BRIDGEWATER, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced that additional REDUCE-IT patient subgroup analysis and additional mechanistic data on potential multifactorial biologic activities will be presented at the American College of Cardiology's Annual Scientific Session & Expo, March 28-30, 2026, in New Orleans, LA....

07.03.26 - 08:00	Here′s Why I Wouldn′t Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks (Fool)
	Amarin is milking a cash cow, but it looks like that cow is slowly being bled to death....

05.03.26 - 16:00	AMRN Stock Soars 37.7% in a Year: Here′s What You Need to Know (Zacks)
	Amarin shares surge 37.7% in a year as restructuring, cost cuts and expanding Vazkepa partnerships for international growth fuel optimism....

03.03.26 - 16:00	Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now (Fool)
	One is speculative, the other is a reliable blue chip company....

25.02.26 - 16:48	Amarin (AMRN) Q4 2025 Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wenn die Leidenschaft oft kühner rät als die Reflexion, so verleiht sie auch mehr Kraft zur Ausführung. - Luc de Clapiers Vauvenargues

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram